Currently available AR antagonists such as bicalutamide have limited activity in castration-resistant prostate cancer (CRPC). Mechanistic studies have shown that the bicalutamide liganded AR can accumulate in the nucleus and bind to chromatin, but that it does not effectively recruit coactivator proteins and instead can recruit the corepressor proteins NCoR and SMRT. This ability to mediate chromatin binding may be an """"""""Achilles Heal"""""""" of these agents, as it could facilitate their acquisition of weak or possibly strong agonist activity in CRPC. In contrast to these currently available antagonists, MDV3100 does not enhance nuclear localization or simulate chromatin binding, and recently reported phase III trial results show that MDV3100 can prolong survival in CRPC. These findings likely will lead to FDA approval of MDV3100 in the near future, arming medical oncologists with two new agents (abiraterone and MDV3100) that can effectively suppress AR activity in CRPC. Therefore, it is now critical to understand in detail mechanisms of action for MDV3100 and related AR antagonists under development, to determine how they might best be used in conjunction with abiraterone, and to identify mechanisms of intrinsic and acquired resistance. Our overall objectives in this proposal are to understand how MDV3100 and functionally related AR antagonists interfere with AR binding to chromatin, and to identify mechanisms of resistance. Our recent studies have shown that phosphorylation of serine 81 (S81) in the AR N-terminal domain is critical for stable binding of AR to chromatin. Moreover, our data indicate that the primary mechanism of action of MDV3100 is to prevent chromatin binding, and that MDV3100 interferes with a S81 dependent step in AR chromatin binding. Based on these findings, our general approach is to determine the molecular basis for S81 dependent AR binding to chromatin (Aim 1) and to determine how MDV3100 and functionally related antagonists interfere with this binding (Aim 2). We will then evaluate candidate mechanisms of MDV3100 resistance in cell line models (Aim 2), and in xenograft models and clinical samples (Aim 3).

Public Health Relevance

The likely FDA approval of MDV3100 will arm oncologists with two new agents (abiraterone and MDV3100) that can suppress AR activity in CRPC, but patients invariably relapse and resistance mechanisms are unknown. Tis proposal will determine in detail the mechanisms of action for MDV3100 and functionally related AR antagonists under development, and identify mechanisms of .intrinsic and acquired resistance.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-O)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beth Israel Deaconess Medical Center
United States
Zip Code
Liu, Xiaming; Han, Weiwei; Gulla, Sarah et al. (2016) Androgen ablation elicits PP1-dependence for AR stabilization and transactivation in prostate cancer. Prostate 76:649-61
Liu, Xiaming; Han, Weiwei; Gulla, Sarah et al. (2016) Protein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation. Oncotarget 7:1754-64
Li, Zhenfei; Alyamani, Mohammad; Li, Jianneng et al. (2016) Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature 533:547-51
Kumar, Akash; Coleman, Ilsa; Morrissey, Colm et al. (2016) Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med 22:369-78
Gao, Shuai; Gao, Yanfei; He, Housheng Hansen et al. (2016) Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein. Cell Rep 17:966-976
Penning, Trevor M; Tamae, Daniel (2016) Current advances in intratumoral androgen metabolism in castration-resistant prostate cancer. Curr Opin Endocrinol Diabetes Obes 23:264-70
Asangani, Irfan A; Wilder-Romans, Kari; Dommeti, Vijaya L et al. (2016) BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer. Mol Cancer Res 14:324-31
Wu, Yu; Schoenborn, Jamie R; Morrissey, Colm et al. (2016) High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer. J Mol Diagn 18:131-43
Mostaghel, Elahe A; Zhang, Ailin; Plymate, Stephen (2016) UDP-glucuronosyltransferase Enzymes in Prostate Cancer Progression: Is Only Androgen Catabolism Involved? Eur Urol 69:610-2
Groner, Anna C; Cato, Laura; de Tribolet-Hardy, Jonas et al. (2016) TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. Cancer Cell 29:846-58

Showing the most recent 10 out of 53 publications